GoodRx Holdings, Inc.

GDRX

Nasdaq; business equipment; SIC 7374, Services-Computer Processing & Data Preparation; CIK 0001809519

D

fourth fifth of 496 graded peers in business equipment

rank 386 of 496; percentile 77.8; sampling error 2.2 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	C percentile 52.3
Solvency	C percentile 54.7
Growth and financing	D percentile 73.6
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 238 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$3.57 2026-10-21; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Our mission is to help Americans save time and money when filling their medications. To achieve this, we are building the leading, consumer-focused digital healthcare platform in the United States. GoodRx was founded to solve the challenges that consumers face in understanding, accessing, and affording healthcare by removing the friction and inefficiencies in the system. We started with a price comparison tool for prescriptions, offering consumers free access to lower prices on their medication.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 52.3						
Gross profitability	not computable	28.6%				
one or more required annual facts are missing						
Return on invested capital	5.8%	11.2%		62.4	134	2025-12-31
Accruals ratio	(9.8%)	(7.3%)		42.3	616	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.3 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 54.7						
Twelve-month failure probability	not computable	0.05%				
liabilities and a nearby cover-page share count are required at 2026-06-30						
Altman Z double-prime	(0.18)	2.15		59.1	563	2025-12-31
Net debt to EBITDA	2.54x	1.11x		68.5	147	2025-12-31
Interest coverage	not computable	3.77x				
one or more required annual facts are missing						
Current ratio	2.61x	2.01x		36.4	660	2025-12-31
Growth and financing, sleeve percentile 73.6						
Revenue growth, three-year compound	1.3%	6.4%		64.3	536	2025-12-31
Free cash flow growth, three-year compound	4.8%	18.1%		69.2	264	2025-12-31
Reinvestment rate	(294.9%)	14.3%		88.8	224	2025-12-31
Asset growth, three years	(4.4%)	5.0%		72.1	561	2025-12-31
Net share issuance, one year	not computable	0.5%				
two annual share counts are required; found 0						

Among 496 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
381	Harvard Bioscience Inc. (HBIO)	76.8	D	
382	Marchex Inc. (MCHX)	77.0	D	
383	Synopsys Inc. (SNPS)	77.2	D	
384	Duos Technologies Group, Inc. (DUOT)	77.4	D	dilution, late filer, fortress balance sheet
385	Spectrum Brands Holdings, Inc. (SPB)	77.6	D	
386	GoodRx Holdings, Inc. (GDRX)	77.8	D	
387	Asure Software Inc. (ASUR)	78.0	D/E	
388	Immersion Corp. (IMMR)	78.2	D/E	late filer, fortress balance sheet
389	SmartRent, Inc. (SMRT)	78.4	D/E	
390	Thermo Fisher Scientific Inc. (TMO)	78.6	D/E	
391	Clarivate plc (CLVT)	78.8	D/E	

What the price implies

at the 2026-10-21 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.5%)	2.2%	32
Distance from 52-week high	(9.6%)	(30.2%)	80
EBIT to enterprise value	not computable	1.5%	
Free cash flow yield	not computable	2.7%	
Book value to price	not computable	0.25	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	not computable	0.32	
Composite equity issuance, five years	not computable	4.2%	
Relative strength against the sector, log excess return	(0.48)	(0.26)	32

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$296.1M
Operating cash flow, four quarters	$201.6M
Months of runway	not finite
Days since last periodic filing	78 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$3.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	$87.5M	2025-12-31	2026-02-26	10-K	26-000031
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$56.5M	2025-12-31	2026-02-26	10-K	26-000031
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$26.1M	2025-12-31	2026-02-26	10-K	26-000031
4	total debt	us-gaap:LongTermDebt	$495.0M	2025-12-31	2026-02-26	10-K	26-000031
5	book equity	us-gaap:StockholdersEquity	$616.3M	2025-12-31	2026-02-26	10-K	26-000031
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$261.8M	2025-12-31	2026-02-26	10-K	26-000031
7	total debt	us-gaap:LongTermDebt	$500.0M	2024-12-31	2025-02-27	10-K	25-000040
8	book equity	us-gaap:StockholdersEquity	$724.7M	2024-12-31	2026-02-26	10-K	26-000031
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$448.3M	2024-12-31	2026-02-26	10-K	26-000031
10	net income	us-gaap:NetIncomeLoss	$30.4M	2025-12-31	2026-02-26	10-K	26-000031
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$167.9M	2025-12-31	2026-02-26	10-K	26-000031
12	assets	us-gaap:Assets	$1.4B	2025-12-31	2026-02-26	10-K	26-000031
13	assets	us-gaap:Assets	$1.4B	2024-12-31	2026-02-26	10-K	26-000031
14	current assets	us-gaap:AssetsCurrent	$643.1M	2025-12-31	2026-02-26	10-K	26-000031
15	current liabilities	us-gaap:LiabilitiesCurrent	$246.0M	2025-12-31	2026-02-26	10-K	26-000031
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.4B	2025-12-31	2026-02-26	10-K	26-000031
17	liabilities	us-gaap:Liabilities	$787.8M	2025-12-31	2026-02-26	10-K	26-000031
18	depreciation amortization	us-gaap:Depreciation	$4.2M	2025-12-31	2026-02-26	10-K	26-000031
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$796.9M	2025-12-31	2026-02-26	10-K	26-000031
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$792.3M	2024-12-31	2026-02-26	10-K	26-000031
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$750.3M	2023-12-31	2026-02-26	10-K	26-000031
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$766.6M	2022-12-31	2025-02-27	10-K	25-000040
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.5M	2025-12-31	2026-02-26	10-K	26-000031
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$183.9M	2024-12-31	2026-02-26	10-K	26-000031
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2M	2024-12-31	2026-02-26	10-K	26-000031
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$138.3M	2023-12-31	2026-02-26	10-K	26-000031
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.0M	2023-12-31	2026-02-26	10-K	26-000031

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$146.8M	2022-12-31	2025-02-27	10-K	25-000040
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.0M	2022-12-31	2025-02-27	10-K	25-000040
30	current assets	us-gaap:AssetsCurrent	$659.3M	2024-12-31	2026-02-26	10-K	26-000031
31	current liabilities	us-gaap:LiabilitiesCurrent	$123.9M	2024-12-31	2026-02-26	10-K	26-000031
32	assets	us-gaap:Assets	$1.6B	2023-12-31	2025-02-27	10-K	25-000040
33	assets	us-gaap:Assets	$1.6B	2022-12-31	2024-02-29	10-K	24-000032

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.